Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab With Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

Trial Profile

Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab With Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Diabetic retinopathy
  • Focus Therapeutic Use
  • Acronyms Protocol S
  • Most Recent Events

    • 18 Apr 2017 According to a Roche media release, the FDA granted ranibizumab (Lucentis) Priority Review for the treatment of diabetic retinopathy without DME based on an analysis of this trial.
    • 18 Apr 2017 Results published in a Roche media release.
    • 17 Apr 2017 Results of subgroup analysis in patients without diabetic macular edema published in a Genentech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top